Of all patients admitted for 3 days or longer and of a sample of patients admitted for less than 3 days, admission (within 48 hours) and twice weekly swabs were taken from the anterior nares (MRSA), perineum (VRE, HRE) and wounds (if present; MRSA, VRE and HRE). The frequency of culturing was reduced to once weekly if the patient had a length of stay (LOS) in ICU longer than 21 days. All cultures were obtained using regular dry swabs by experienced ICU nurses or the appointed research nurses.
Figure 1
containing disk, often resulting in a characteristic shape-zone referred to as 'champagne-cork' or 'keyhole'. DDST was performed on Mueller-Hinton agar according to CLSI guidelines for non-fastidious bacteria. Colonies that showed a positive DDST were considered to be HRE positive.
Use of PCR tests
For detection of MRSA and VRE on admission swabs, Xpert MRSA and Xpert VanA/VanB (Cepheid, Sunnyvale, CA USA) were used with the GeneXpert platform. The manufacturer at each site provided training and instructions on the use of the PCR. Double-headed swabs were used to facilitate use of the surveillance swab for both PCR and chromogenic agar. Swabs were labelled appropriately with the information written in permanent/nonremovable ink. During phase 3 of the study, screening swab samples were directly processed and were not frozen and stored.
Each test was started within 15 minutes of adding the reagents to the cartridge.
The cartridge and reagents were removed from the package. Swabs were removed from the transport container and then one swab was removed from the red cap. The swab was inserted into the tube containing the Elution Reagent (using sterile gauze to minimize risks of contamination). The swab was held by the stem near the rim of the tube, lifted a few millimetres from the bottom of the tube and the stem pushed against the edge of the tube to break it. The cap was closed tightly and vortexed at high speed for 10 seconds. The cartridge lid was opened. Using a sterile transfer pipette, the entire contents of the Elution Reagent were transferred to the "S" chamber of the GeneXpert MRSA or Xpert vanA/vanB cartridge. Reagent 1 was added into cartridge chamber 1. The ampoule was squeezed until the entire  Dispose of the used cartridges in the appropriate specimen waste containers according to your institution's standard practices.
Transport of strains:
Two microbanks with beads and liquid medium were provided to the sites for storage of each strain (one microbank for the MOSAR central laboratory and one microbank as back-up; to be stored at the hospital site). For storage of the strains, the screw cap of the microbank was opened under aseptic conditions. A large disposable 10 µl loop or a swab was used to pick up as many colonies as possible and was dispensed in the microbank medium by rotating the loop several times to make sure the bacteria were completely dispersed in the fluid. The vial was closed tightly, inverted 4-5 times and vortexed for 20-25 seconds to let more bacteria stick to the beads. The vial was opened again and excess fluid removed with a sterile plastic Pasteur pipette. The vial was then re-capped and screwed as tight as possible. Both microbanks from one strain were stored together preferably at -70°C, and if not available at -20°C in the freezer until shipment to the central laboratory.
From each patient, the first isolated strain of MRSA, VRE and each different HRE was shipped to the central laboratory for confirmation and molecular typing. Shipment was in one or more batches per centre; 1 microbank per strain was shipped on dry ice in small boxes (one box could hold ~100 microbanks).
I Chlorhexidine gluconate body washing protocol

Selection of patients
All patients that are present on the ICU on the first day of phase 2 of the trial, and all patients admitted to the ICU after that day will be bathed daily for the whole length of their stay with chlorhexidine gluconate, unless there is a contra-indication.
If there is a contra-indication, please note this clearly at the patient's bed space and use appropriate alternative bathing methods.
Contra-indications
•
Burn patients 
Product
Any product of 4% chlorhexidine (digluconate) that can be dissolved in warm water may be used.
Preparation of washing solution
Dissolve a 4 fluid ounce bottle of 4% chlorhexidine (digluconate) in 6 quarts of warm water (=one washing basin)
In the metric system, the amounts equal:
• 120 mL of chlorhexidine in 6 litres of warm water 
Body lotion/ skin care
Because chlorhexidine is a cationic molecule, its activity can be reduced by natural soaps, various inorganic anions, non-ionic surfactants, and hand creams containing anionic emulsifying agents. Use an approved lotion for skin care of the patient; make sure you check this in the package insert of the chlorhexidine product
Adverse reaction
Chlorhexidine is a product that has been extensively investigated and used. It is registered for the indication of skin antisepsis and side effects have seldom been described. However, with any product adverse reaction can occur. If a patient without a history of allergy against the product develops a (possible) adverse reaction to the chlorhexidine body washing (e.g.: skin rash), do not continue daily bathing with chlorhexidine.
II Hand hygiene improvement program
Design of the intervention
Dedicated research nurses are trained in direct observation of hand hygiene, using the WHO method of observation. Training occurs through centralized full-day teaching sessions, distribution of training materials, and access to all online WHO resources (http://www.who.int/gpsc/en/). The trained research nurses are responsible for observations, and for locally implementing the hand hygiene improvement program after phase 1, which includes educational sessions, visual reminders and direct feedback after observations. Monthly feedback of local compliance rates is provided to ICUs to guide the content of each local hand hygiene program. Newsletters and monthly conference calls will be initiated to share ideas and address questions related to the conduct of the study. In phase 3, monitoring and feedback will be continued; whist the hand hygiene improvement program is maintained as much as possible. The five different indications for hand hygiene in the WHO concept are separated into indications that occur before an action ("before patient" and "before aseptic"), and indications occurring after an action ("after patient", "after body fluid" and "after surroundings"). The "before" indications protect the patient, whereas the "after" indications protect health care workers and the patients' environment (and ultimately other patients).
Data collection and monitoring
The WHO form (with minor adaptations for this study, Figure 2 ) is used to register observed opportunities for HH, and data are entered within a week in an online case record form. During the trial, the research coordinators visit all sites. During these visits, methods of observation are reviewed and 10% of the monitoring forms crosschecked with data entered into the online case record form. Written scenarios as well as newsletters and conference calls are used throughout the trial to continuously validate observers' methods.
Informing ICU staff
Prior to the initiation of bedside monitoring, the ICU staff should be informed about the purpose and general procedures for bedside monitoring. ICU staff should be informed that:
--The purpose of these observations is to determine if differences in patient care practices occur:
1) Between ICUs randomized to the two different strategies during the intervention period in order to assess the effect of both strategies 2) Between the baseline and intervention periods in all ICUs to assess the effect of the Hygiene Improvement Program --The purpose of these observations is not to evaluate and critique practices of individual healthcare workers or individual ICUs.
--Data will be recorded regarding the opportunities for hand hygiene and the type of action taken.
Possible actions taken are hand washing, hand rubbing, using gloves or missing the opportunity to perform hand hygiene. No unique identifying data regarding the patient or the healthcare worker will be recorded.
--Monitoring will occur on random dates at random times; bed spaces will be chosen at random.
--Monitors will be present in the room for approximately 30 minutes, or until the maximum amount of opportunities and/ or professionals have been observed. The monitoring form allows observation of a maximum of 9 opportunities for hand hygiene for a maximum of 4 professionals.
--Monitors will stand in a spot where they can observe patient care. Monitors may be asked to move, if necessary.
--Monitors cannot assist in patient care. If a healthcare worker is not present in the room, monitors will notify healthcare workers immediately about urgent patient care issues (e.g.: patient attempting to remove catheter or get out of bed unassisted). Routine requests or questions from patients and family will be referred to a healthcare worker when he or she returns to the room.
--Healthcare workers, patients, or family members may request that the bedside monitor not perform observations or stop observations at any time for any reason.
--The cooperation of healthcare workers with bedside monitoring is greatly appreciated.
Instructions for the bedside monitor
The worksheet/ observation form can be downloaded from the website (www.mosar-sic.org).
--Complete the top portions of the worksheet (date of the performed observation, start & stop time using a 24-hour clock, your initials and the bed space number).
--Identify the location of the sink for hand washing and any bottles or dispensers of alcohol-based waterless hand rub, gel, or foam in the room or immediately outside the room. Identify where gloves and gowns for use in the room are kept and where they are disposed.
4.
--Observe closely for any opportunity for hand hygiene that occurs, and whenever one occurs; check the appropriate "moment" and corresponding action on the worksheet --After completing the observations from the 4-hour interval, the data collected on the worksheets must be entered into the electronic recording system. Data from all sessions, completed and uncompleted, should be entered into the online data capturing system.
--The monitor should save and store the worksheets in a separate binder/folder and file forms in reverse chronological order (i.e. every new worksheet is placed on top of the filed worksheets).
Schedule of monitoring dates and time intervals
--Each site will be supplied with a list of pre-selected dates and 4-hour intervals for monitoring. The following 4-hour time intervals will be used on the schedule: 08:00-12:00 hrs, 12:00-16:00 hrs, 16:00-20:00 hrs. There will be no compulsory monitoring on weekends or at nights.
--A session is defined as the time spent observing one bedside. For example, for the 4-hour time interval of 8 am-12 pm, the observation period could be from 10 am to 11 am and consist of two 30-minute sessions observing one bed space each.
--If the monitor is unable to perform observations on a scheduled day during the scheduled time-interval, they should plan to "make-up" these observations during the same 4-hour time interval on a date as close as possible to the scheduled date. The make-up day may occur before or after the scheduled day but the time interval must be the same.
--The monitor may make-up no more than 1 observation period on any given day. A make-up observation period may occur on a day that is also a scheduled day but the time intervals for the make-up time interval and the scheduled time interval must remain as originally scheduled.
Selection of bed spaces
--For each 30-minute session, the monitor will identify a bed space to monitor using a random number --The monitor will review the list of random numbers and identify the next unused random number on the list. The monitor will determine the ICU bed space number associated with that number, and cross off the random number on the table so that it is no longer available. If the random number does not have an associated bed space, that number will be crossed off and the next number will be chosen.
--If a patient occupies the bed space, the monitor will observe the contact by health care workers in that bed space. If there is no patient in the bed space, the next random number will be chosen and the associated bed space will be monitored if a patient occupies it.
--If a patient who is on airborne precautions occupies the bed space, that bed space will not be observed. The next random number will be chosen and the associated bed space will be monitored if a patient occupies it.
Completed sessions
If an observation period ends before 30 minutes, and before the maximum amount of opportunities has been observed, the reason the session was ended early should be recorded on the paper worksheet. If the period was 15 minutes or longer, it qualifies as a completed session. If it was shorter than 15 minutes, the session does not quality as a completed session. Data from all sessions, completed and uncompleted, should be entered into the electronic record system. • If no MRSA or VRE or ESBL was confirmed by chromagar and PCR was negative > remove contact precautions for this patient, go to point 5
Materials
• If MRSA or VRE or ESBL was confirmed by chromagar and PCR was negative > keep contact precautions for this patient 5. On the next Monday or Thursday, new swabs will be taken.
• If the patient is not on contact precautions when taking these swabs, start this protocol from point 3
• If the patient is isolated when taking these swabs
• Only remove contact precautions if all cultures and confirmation tests for two consecutive screening cultures are negative
• After removing contact precautions, start this protocol from point 5
Contact precautions protocol in phase 3
If a patient has an indication for contact precautions the following procedure will be implemented:
--On the bed of the patient a notice/ sign will be clearly visible, stating the micro-organism the patient is colonized with (e.g.: "MRSA positive")
Note: Please distinguish signs for "suspected colonization" and "proven colonization"
--The patient will be put in a single room, and gloves and gowns will be used for all procedures involving patient contact. The "contact precautions" rules below should be followed. Supplies for proper hand hygiene should be available at the bedside.
--If you do not have a single room available for the colonized patient, then nurse cohorting should be used in the care of this patient. This means that preferably one nurse should care for all patients colonized with the same micro-organism. Also, gloves and gowns will be used for all procedures involving patient contact. The "contact precautions" rules below should be followed. Supplies for proper hand hygiene should be available at the bedside. Avoid unnecessary contact with healthcare workers.
--If you do not have a single room available for the colonized patient, patients carrying the same microorganism should be cohorted in double-or multi-patient rooms. Also, gloves and gowns will be used for all procedures involving patient contact. The "contact precautions" rules below should be followed.
Supplies for proper hand hygiene should be available at the bedside.
--In multi-patient rooms, 3 or more feet spatial separation of beds is advised.
Contact precautions rules
--Health care workers caring for patients on contact precautions wear a gown and gloves for all interactions that may involve contact with the patient or potentially contaminated areas in the patient's environment. The patient's environment includes the bed, bed linen, equipment, and items and surfaces in the patient's room or bed space (if the patient is in a multi-patient room).
--Use of gloves and a gown are additional precautions to reduce hand and clothing contamination during care of a patient requiring contact precautions. Use of gloves and a gown is not a replacement for hand hygiene or other elements of standard precautions (i.e., use of mouth, nose, eye protection, as indicated).
--Clean gloves and a clean gown should be put on when entering the patient's room or bed space and be worn during all contact with the patient and with the patient's environment (all items and surfaces in the patient's room or bed space);
--Gloves should be changed and hand hygiene performed after direct contact with the patient (before touching items and surfaces in the environment), after contact with blood, body fluids, secretions, excretions, mucous membranes, or non-intact skin;
--If care of the patient will be continued, a new clean pair of gloves should be put on;
--The gown should be changed if it becomes visibly soiled or is likely to have become contaminated (i.e., the healthcare worker has direct, close physical body contact with the patient, such as might occur during transfer from the bed to a chair or commode, or contact with the patient's bed linen, such as might occur during a change of the patient's bed linen);
--If care of the patient will be continued, a clean gown should be put on;
--Gloves and the gown should be removed and hand hygiene performed when leaving the room;
--Contact precautions can be combined with other transmission-based isolation precautions as clinically indicated.
Contact precautions in phase 1 and 2
Use of contact precautions during phase 1 and 2 is according to local protocols, and may include contact 
Calendar month Enterobacteriaceae ; CI = confidence interval; aIRR = adjusted incidence rate ratio; P1 = phase 1; P2 = phase 2; P3 = phase 3; CA = conventional arm; RA = rapid arm; LRT = likelihood ratio test.
Shown are model results from multilevel Poisson segmented regression, allowing for ICU-level random effects for the intercept and P1 trend, and with an unstructured covariance matrix. A log link function was used so trend terms are assumed to be exponential. All models included an offset term to account for the weekly exposure in each ICU (number of days at risk for acquiring each organism, where a patient was considered at risk on any day prior to the first positive isolate for the specified organism or, if never positive, prior to the last negative swab). Ratio; P1 = phase 1; P2 = phase 2; P3 = phase 3; CA = conventional arm; RA = rapid arm.
Shown is survival analysis using a Cox regression model stratified by ICU where failure events correspond to acquisition of MRSA, VRE or HRE and patients are censored at ICU discharge.
Acquisition is assumed to occur two days before the first positive isolate. aHRs greater than one indicate that a variable is associated with an increased risk of the failure event in a small time interval; aHRs less than one correspond to decreased risk. Analysis using a frailty model with random effects showed a similar effect (data not shown). 
